Abstract: Objective To investigate the effects of docetaxel and epirubicin neoadjuvant chemotherapy on
regulatory T cells of patients with liver cancer. Methods Total of 120 patients with liver cancer in Dongfeng
Hospital of Hubei Medical College from August 2011 to December 2014 were selected and randomly
divided into treatment group and control group according to the draw principles, 60 cases in each group.
All patients completed liver resection successfully. The treatment group were given postoperative docetaxel
plus doxorubicin chemotherapy and the control group were given postoperative oxaliplatin platinum
plus capecitabine chemotherapy. Total efficiency and adverse events of chemotherapy were observed
and the immune functions were detected. Results After chemotherapy, the number of CD4 + CD25 + Treg
cells decreased significantly in the two groups (P = 0.000), and the number of CD4 + CD25 + Treg cells in
the treatment group was significantly lower than that of the control group (P = 0.000). The CD4 + /CD8 +
and CD3 + values decreased significantly after chemotherapy in both groups, and the treatment group was
significantly higher than that of the control group (P = 0.000). The adverse reactions in the two groups
during chemotherapy were nausea, vomiting, leukopenia and thrombocytopenia, and incidence of the adverse
reactions in the treatment group were significantly lower than that of the control group (P = 0.000). After
chemotherapy, the total efficiency of the treatment group (80.0%) was significantly higher than that of the
control group (50.0%) (P = 0.000). Conclusion Docetaxel plus epirubicin for adjuvant chemotherapy of liver
cancer can improve the anti-tumor effect, and reduce the incidence of adverse reactions, which plays a role of
restoring regulatory T lymphocytes and cell activity.